Ozanezumab治疗肌萎缩侧索硬化症的安全性和有效性:一项随机双盲安慰剂对照2期试验
这项在11个国家34个中心开展的随机双盲安慰剂对照2期试验,纳入303例肌萎缩侧索硬化症(ALS)患者,评估ozanezumab(15 mg/kg,每2周静脉输注)与安慰剂的疗效和安全性。Ozanezumab未显示出优于安慰剂的疗效,提示Nogo-A可能不是ALS的有效治疗靶点。
要点
- Ozanezumab在ALS患者中未显示出优于安慰剂的疗效。
- 安全性方面,ozanezumab组消化不良、抑郁和腹泻报告率略高。
核心结论
- Ozanezumab与安慰剂相比在ALS患者中未显示出疗效,Nogo-A似乎不是ALS的有效治疗靶点。
研究设计与样本
- 随机、双盲、安慰剂对照的2期试验,在11个国家34个中心进行。
- 纳入18-80岁 familial 或散发性ALS患者,随机(1:1)接受ozanezumab(15 mg/kg)或安慰剂静脉输注,每2周1次,持续46周,第48周和第60周评估。
- 共招募307例患者,303例随机分配(安慰剂组151例,ozanezumab组152例)。
- 主要终点为48周时ALS功能评定量表修订版(ALSFRS-R)功能与总生存的联合秩分析,纳入至少接受一剂研究药物的所有患者。
主要发现
- 呼吸衰竭是最常见的严重不良事件(ozanezumab组12例[8%] vs 安慰剂组7例[5%])。
- 两例死亡被认为与研究药物相关(ozanezumab组膀胱移行细胞癌,安慰剂组脑血管意外)。
临床怎么用
- 不推荐将ozanezumab用于ALS患者的治疗。
- 针对Nogo-A通路的治疗策略在ALS中需重新评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neurite outgrowth inhibitor A (Nogo-A) is thought to have a role in the pathophysiology of amyotrophic lateral sclerosis (ALS). A monoclonal antibody against Nogo-A showed a positive effect in the SOD1G93A mouse model of ALS, and a humanised form of this antibody (ozanezumab) was well tolerated in a first-in-human trial. Therefore, we aimed to assess the safety and efficacy of ozanezumab in patients with ALS. METHODS: This randomised, double-blind, placebo-controlled, phase 2 trial was done in 34 centres in 11 countries. Patients aged 18-80 years with a diagnosis of familial or sporadic ALS were randomly assigned (1:1), centrally according to a computer-generated allocation schedule, to receive ozanezumab (15 mg/kg) or placebo as intravenous infusions over 1 h every 2 weeks for 46 weeks, followed by assessments at week 48 and week 60. Patients and study personnel were masked to treatment assignment. The primary outcome was a joint-rank analysis of function (ALS Functional Rating Scale-Revised) and overall survival, analysed at 48 weeks in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01753076, and with GSK-ClinicalStudyRegister.com, NOG112264, and is completed. FINDINGS: Between Dec 20, 2012, and Nov 1, 2013, we recruited 307 patients, of whom 303 were randomly assigned to receive placebo (n=151) or ozanezumab (n=152). The adjusted mean of the joint-rank score was -14·9 (SE 13·5) for the ozanezumab group and 15·0 (13·6) for the placebo group, with a least squares mean difference of -30·0 (95% CI -67·9 to 7·9; p=0·12). Overall, reported adverse events, serious adverse events, and adverse events leading to permanent discontinuation of study drug or withdrawal from study were similar between the treatment groups, except for dyspepsia (ten [7%] in the ozanezumab group vs four [3%] in the placebo group), depression (11 [7%] vs five [3%]), and diarrhoea (25 [16%] vs 12 [8%]). Respiratory failure was the most common serious adverse event (12 [8%] vs seven [5%]). At week 60, the number of deaths was higher in the ozanezumab group (20 [13%]) than in the placebo group (16 [11%]), mainly as a result of respiratory failure (ten [7%] vs five [3%]). Two deaths were considered related to the study drug (bladder transitional cell carcinoma in the ozanezumab group and cerebrovascular accident in the placebo group). INTERPRETATION: Ozanezumab did not show efficacy compared with placebo in patients with ALS. Therefore, Nogo-A does not seem to be an effective therapeutic target in ALS. FUNDING: GlaxoSmithKline.
引用
- Meininger V, Genge A, van den Berg LH, et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017. PMID: 28139349. doi:10.1016/S1474-4422(16)30399-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。